James G. Robertson

Discovery and Preclinical Profile of Saxagliptin (BMS-477118):  A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

David J. Augeri, Jeffrey A. Robl, David A. Betebenner et al. · Journal of Medicinal Chemistry · 2005 · 617 citations · Full text

Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

Wei Meng, Bruce A. Ellsworth, Alexandra A. Nirschl et al. · Journal of Medicinal Chemistry · 2008 · 612 citations · Full text

Metabolic Syndrome, Diabetes Management, Biochemistry +10

4-Thiazolidinones: novel inhibitors of the bacterial enzyme murB

Charles J. Andres, Joanne J. Bronson, Stanley V. D’Andrea et al. · Bioorganic & Medicinal Chemistry Letters · 2000 · 218 citations

Medicine, Bacterial Enzyme Murb, Antibacterial Agent +6

Synthesis of Novel Potent Dipeptidyl Peptidase IV Inhibitors with Enhanced Chemical Stability:  Interplay between the N-Terminal Amino Acid Alkyl Side Chain and the Cyclopropyl Group of α-Aminoacyl-<scp>l</scp>-<i>cis</i>-4,5-methanoprolinenitrile-Based Inhibitors

David R. Magnin, Jeffrey A. Robl, Richard Sulsky et al. · Journal of Medicinal Chemistry · 2004 · 103 citations · Full text

Glycobiology, Methanoprolinenitrile-containing Dipeptide Mimetics, Pharmacotherapy +19

Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2

Bruce A. Ellsworth, Wei Meng, Manorama M. Patel et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 57 citations · Full text

C-arylglucoside Inhibitors, Renal Function, Biochemistry +10